B
Barry S. Zingman
Researcher at Albert Einstein College of Medicine
Publications - 56
Citations - 2809
Barry S. Zingman is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Viral load & Lopinavir. The author has an hindex of 20, co-authored 56 publications receiving 2493 citations. Previous affiliations of Barry S. Zingman include Yeshiva University & City University of New York.
Papers
More filters
Journal ArticleDOI
Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Judith A. Aberg,Joel E. Gallant,Khalil G. Ghanem,Patricia Emmanuel,Barry S. Zingman,Michael A. Horberg +5 more
TL;DR: These updated guidelines replace those published in 2009 and recommend that HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems.
Journal ArticleDOI
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey,Till Schoofs,Henning Gruell,Allison Settler,Theodora K. Karagounis,Edward F. Kreider,Ben Murrell,Nico Pfeifer,Lilian Nogueira,Thiago Y. Oliveira,Gerald H. Learn,Yehuda Z. Cohen,Clara Lehmann,Daniel Gillor,Irina Shimeliovich,Cecilia Unson-O’Brien,Daniela Weiland,Alexander. Robles,Tim Kümmerle,Christoph Wyen,Rebeka Levin,Maggi Witmer-Pack,Kemal Eren,Caroline Ignacio,Szilard Kiss,Anthony P. West,Hugo Mouquet,Barry S. Zingman,Barry S. Zingman,Roy M. Gulick,Tibor Keler,Pamela J. Bjorkman,Michael S. Seaman,Beatrice H. Hahn,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig,Michel C. Nussenzweig,Florian Klein +38 more
TL;DR: The results demonstrate the safety and activity of 10-1074 in humans and support the idea that antibodies targeting the V3 glycan supersite might be useful for the treatment and prevention of HIV-1 infection.
Journal ArticleDOI
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid,Johannes F. Scheid,Joshua A. Horwitz,Yotam Bar-On,Edward F. Kreider,Ching-Lan Lu,Julio C. C. Lorenzi,Anna Feldmann,Malte Braunschweig,Lilian Nogueira,Thiago Y. Oliveira,Irina Shimeliovich,Roshni Patel,Leah A. Burke,Yehuda Z. Cohen,Sonya Hadrigan,Allison Settler,Maggi Witmer-Pack,Anthony P. West,Boris Juelg,Tibor Keler,Thomas Hawthorne,Barry S. Zingman,Roy M. Gulick,Nico Pfeifer,Gerald H. Learn,Michael S. Seaman,Pamela J. Bjorkman,Florian Klein,Florian Klein,Florian Klein,Sarah J. Schlesinger,Bruce D. Walker,Bruce D. Walker,Beatrice H. Hahn,Michel C. Nussenzweig,Marina Caskey +36 more
TL;DR: It is concluded that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans, suggesting failure to escape over a period of 9-19 weeks.
Journal ArticleDOI
Executive Summary: Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Judith A. Aberg,Joel E. Gallant,Khalil G. Ghanem,Patricia Emmanuel,Barry S. Zingman,Michael A. Horberg +5 more
TL;DR: These updated guidelines replace those published in 2009 and recommend that HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems.
Journal ArticleDOI
HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
TL;DR: Moderate levels of adherence can lead to virologic suppression in most patients taking lopinavir/ritonavir-based HAART, and this study aims to define the level of adherence needed to achieve virologics suppression in patients receiving boosted PI-based highly active antiretroviral therapy (HAART).